Quest Diagnostics Inc
NYSE:DGX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Arr Planner Co Ltd
TSE:2983
|
JP |
|
Anshin Guarantor Service Co Ltd
TSE:7183
|
JP |
Quest Diagnostics Inc
Narrow
Economic Moat
Narrow moat driven primarily by proprietary data and scale-based advantages, reinforced by entrenched payer and hospital relationships that raise rivals’ barriers to entry.
Quest Diagnostics Inc
Competitive Advantages
Extensive in‑network payer contracts and embedded hospital partnerships/CoLab solutions create operational and contractual frictions that make it costly for customers and health systems to move testing volume to competitors. ([pestel-analysis.com](https://pestel-analysis.com/products/questdiagnostics-marketing-mix?utm_source=openai))
Largest proprietary de-identified clinical-data repository and broad test menu that Quest monetizes for analytics and advanced diagnostics, creating unique, hard-to-replicate diagnostic intelligence. ([ebusiness.com](https://ebusiness.com/report/questdiagnostics.com?utm_source=openai))
Nationwide, centralized laboratory network plus automation and process programs (e.g., INFIGURATE/automation initiatives) deliver scale economies in throughput, turnaround time, and cost per test. ([fool.com](https://www.fool.com/earnings/call-transcripts/2026/02/10/quest-diagnostics-dgx-earnings-call-transcript/?utm_source=openai))
Wide Economic Moat Companies
| Company | Last Price | Price Change | Market Cap | Economic Moat | ||
|---|---|---|---|---|---|---|
|
|
|
NVIDIA Corp
NVDA
|
$188.63 |
+0.9%
|
$4.6T | Wide |
|
|
|
Apple Inc
AAPL
|
$260.48 |
+2.1%
|
$3.8T | Wide |
|
|
|
Alphabet Inc
GOOGL
|
$317.24 |
-0.2%
|
$3.8T | Wide |
|
|
|
Microsoft Corp
MSFT
|
$370.87 |
+1%
|
$2.8T | Wide |
|
|
|
Amazon.com Inc
AMZN
|
$238.38 |
+1.8%
|
$2.6T | Wide |
|
|
|
Taiwan Semiconductor Manufacturing Co Ltd
2330
|
NT$1 990 |
+2.6%
|
$1.6T | Wide |
|
|
|
Meta Platforms Inc
META
|
$629.86 |
+0.1%
|
$1.6T | Wide |
|
|
|
Broadcom Inc
AVGO
|
$371.55 |
-2.1%
|
$1.8T | Wide |
|
|
|
Walmart Inc
WMT
|
$126.77 |
+0.6%
|
$1T | Wide |
|
|
|
Eli Lilly and Co
LLY
|
$939.47 |
-1.3%
|
$888.2B | Wide |
| Company | Last Price | Price Change | Market Cap | Economic Moat | ||
|---|---|---|---|---|---|---|
|
|
|
AstraZeneca PLC
AZN
|
GBX15 230 |
-0.1%
|
$318.7B | Wide |
|
|
|
Kweichow Moutai Co Ltd
600519
|
¥1 455.39 |
+1.7%
|
$264.8B | Wide |
|
|
|
Novo Nordisk A/S
NOVO B
|
kr241 |
-1.9%
|
$168.8B | Wide |
|
|
|
Zhongji Innolight Co Ltd
300308
|
¥739.14 |
+2.6%
|
$119.3B | Wide |
|
|
|
Advantest Corp
6857
|
¥24 990 |
+7.3%
|
$118.3B | Wide |
|
|
|
Eoptolink Technology Inc Ltd
300502
|
¥519.7 |
+2.7%
|
$75B | Wide |
|
|
|
Disco Corp
6146
|
¥66 890 |
+5.3%
|
$46.9B | Wide |
|
|
G
|
Gold Fields Ltd
GFI
|
Zac80 076 |
-1.5%
|
$44.9B | Wide |
|
|
|
Suzhou TFC Optical Communication Co Ltd
300394
|
¥361.96 |
-4.1%
|
$40.9B | Wide |
|
|
|
GE Healthcare Technologies Inc
GEHC
|
$73.18 |
+0%
|
$33.4B | Wide |
Quest Diagnostics Inc
Glance View
In the rapidly evolving world of healthcare, Quest Diagnostics Inc. stands as a pivotal player, shaping the future of diagnostic services. Born out of a quest for innovation in clinical testing, Quest Diagnostics operates at the intersection of medical science and cutting-edge technology. The company has a wide-reaching network of laboratories and service centers, offering a comprehensive array of diagnostic testing solutions that range from routine blood tests to advanced genetic screening. Their services are not limited to hospitals and physician offices; they extend into a variety of sectors including pharmaceuticals, food, and global business services, completing over a hundred million clinical laboratory tests annually. Quest's robust infrastructure and commitment to precision ensure that patients and healthcare providers receive timely and accurate information that is crucial for early detection, diagnosis, and informed treatment decisions. Quest Diagnostics' revenue model is straightforward yet effective, driven primarily by service fees from its expansive menu of tests. By collaborating with insurers, healthcare providers, and employers, Quest ensures broad access to its services. Moreover, the company continually invests in research and development to expand its test portfolio and enhance the quality of its services, thus staying competitive in the fast-paced healthcare environment. Through strategic acquisitions and partnerships, Quest has broadened its geographical reach and bolstered its technological capabilities, maintaining its position as an industry leader. As healthcare increasingly leans toward personalized medicine and preventive care, Quest Diagnostics is poised to leverage its analytical prowess and deep repository of health data to drive future growth and innovation, serving as an indispensable ally in global public health.
Our research into Economic Moat performance spans the past 10 years and focuses on companies with a wide economic moat. For this analysis, we calculated the average stock price returns of these companies, comparing them to the performance of the S&P 500 index over the same period.
The results were compelling: wide moat stocks achieved a remarkable +645% average return, compared to +188% for the broader market. This difference highlights the long-term benefits of investing in businesses that can maintain their market position and pricing power over time.
Note: This research does not account for survivorship bias. Past performance is not indicative of future results.
Economic Moat